Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Nobel Laureates lecture about immune checkpoint therapy for cancer treatment

The Nobel Lectures held by the laureates of the 2018 Nobel Prize in Physiology or Medicine saw Aula Medica at Karolinska Institutet filled to the brink. In addition to 1,000 audience members in the auditorium, people around the world were able to watch the live broadcast when James P. Allison and Tasuku Honjo talked about their research, the results of which have led to the ground-breaking immune checkpoint therapy for cancer treatment.

12 Dec 2018

Slow-growing type of glioma may be vulnerable to immunotherapy, suggests study

Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant.

11 Dec 2018

Researchers examine why HIV-infected patients have higher rates of cancer

AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer--among the leading causes of death among that population--than the general population.

5 Dec 2018

Bacterial infections may contribute to far more cancers than previously thought, shows study

The Institute of Human Virology at the University of Maryland School of Medicine announced today the discovery that DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell's ability to respond to and repair DNA damage, a known origin of cancer.

5 Dec 2018

CAR-T cell therapy appears to be promising option for treating large B-cell lymphoma

So-called CAR-T cell therapy is a promising option for treating around a fifth of patients with diffuse large B-cell lymphoma.

4 Dec 2018

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy Yescarta remained in remission more than two years following therapy, and more than half of the patients treated remain alive.

4 Dec 2018

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

University of North Carolina Lineberger Comprehensive Cancer Center researchers reported promising early results from a clinical study of an investigational cellular immunotherapy that used a patient's own, genetically engineered immune cells to recognize and fight Hodgkin and non-Hodgkin lymphoma cells.

4 Dec 2018

New strategies may improve performance of CAR-T cell therapy in treating cancer

Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

3 Dec 2018

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

Chimeric antigen receptor T-cell therapy, or CAR T, was named the 2017 Advance of the Year by the American Society of Clinical Oncology. The FDA approved two CAR T products last year for treatment of adult large B-cell lymphoma based on the exceptional patient outcomes seen in clinical trials.

3 Dec 2018

UK scientists find new way to identify patients with aggressive lymphoma

UK scientists have found a new way to identify people with the most aggressive types of lymphoma who are less likely to respond to standard drugs.

3 Dec 2018

SSB enters into collaboration with Immunochina to develop new immunotherapy equipment

Sartorius Stedim Biotech, a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced today that both parties have entered into a collaboration.

3 Dec 2018

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.

3 Dec 2018

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

3 Dec 2018

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

29 Nov 2018

Research may pave way for development of potent weapons against cancer

Despite significant advances in cancer research, the disease continues to exact a devastating toll. Because cancer is a disease of the body's own cells, which mutate and develop under evolutionary pressure, conventional treatments like chemotherapy and radiation often leave behind a residue of resistant cells that go on to expand and wreak havoc.

27 Nov 2018

Lymphoma News and Research

Further Reading

Nobel Laureates lecture about immune checkpoint therapy for cancer treatment

Slow-growing type of glioma may be vulnerable to immunotherapy, suggests study

Researchers examine why HIV-infected patients have higher rates of cancer

Bacterial infections may contribute to far more cancers than previously thought, shows study

CAR-T cell therapy appears to be promising option for treating large B-cell lymphoma

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

New strategies may improve performance of CAR-T cell therapy in treating cancer

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

UK scientists find new way to identify patients with aggressive lymphoma

SSB enters into collaboration with Immunochina to develop new immunotherapy equipment

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Research may pave way for development of potent weapons against cancer

Scientists identify key component of microscopic machinery that drives cell death

New first-line treatment for peripheral T-cell lymphoma approved by FDA

Researchers unravel mystery of NPM1 protein in acute myeloid leukemia

New study sheds light on how CAR T cell therapy works

Mutant p53 protein 'tackles' DNA guardian to drive tumor development

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News